High-end preparations are an important direction for pharmaceutical enterprises to innovate, and the construction of industrialization bases in this field is "in full swing
Time of Update: 2023-01-05
For all localities and pharmaceutical companies are vigorously building high-end preparation R&D industrial park projects, the industry believes that this will further optimize the production process of foreign enterprises' preparation products, reduce production costs, improve product quality and performance, enhance the core competitiveness of enterprises, and promote the rapid development of enterprises.
Shanghai Haocang won the first prize of the Science and Technology Award of Guangdong Municipal Industry Association
Time of Update: 2023-01-04
【Chemical Machinery and Equipment Network Star Enterprise】Recently, Shanghai Haocang System Control Technology Co. , Ltd. and Guangzhou Science City Water Investment Group Co. , Ltd. jointly declared
Focusing on the "double carbon" proposition of the two sessions, Far East Endeavor to write a green "answer sheet
Time of Update: 2022-11-28
(Jang Jingjing) With the focus on the main business in recent years, Far East Horizon has continued to increase R&D investment in clean energy, green buildings, nuclear-grade cables, new energy charging pile cables and other subdivisions, and promoted the construction of major projects.
The first generic was suspended from procurement, and the "patent war" of the original V.S. generic drug company continued
Time of Update: 2022-11-15
GGBI SOURCE drug patent radar Source: _msthash="320191" _msttexthash="88454847">Previously, on September 22, the Guangzhou Public Resources Exchange Center also issued an announcement, saying that in order to do a good job in the protection of intellectual property rights in the process of drug hanging online, the procurement platform of Guangzhou Pharmaceutical Group will suspend the qualification of linagliptin tablets (5mg, 7 tablets / box) of Guangdong East Sunshine Pharmaceutical Co.
The application of AM5SE series microcomputer protection measurement and control device in the power supply capacity enhancement transformation of a smelting steel power plant
Time of Update: 2022-10-19
Renyunye Ankrui Electric Co. , Ltd. Jiading, Shanghai 201800 Abstract: A metallurgical steel power plant originally had 6kV two-section busbar, and now added a new section III busbar, through the new
Express Improved antibody-coupled drugs target a variety of solid tumors, and the new sharp completed a $68 million Series A financing
Time of Update: 2022-10-13
▲Pheon R&D pipeline (Source: Pheon official website)Pheon's main project, PHN-010, targets a target that is highly expressed in many solid tumors (target names have not yet been revealed) and is expected to file for a new drug clinical trial (IND) application over the next 18 months.
Immune-Related Adverse Reactions: An Overview
Time of Update: 2022-06-14
1. Anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody: ipilimumab incidence of immune-related adverse events (irAEs) Ipilimumab is the first ICI to enter clinical trials, and its toxicity profile is the clearest .
CNOOC A-share IPO debut meeting
Time of Update: 2022-04-19
In the meeting of the Issuance Review Committee of the China Securities Regulatory Commission held last week, CNOOC's A-share IPO application was approved, and it will soon become the last A-share listed company in the "Three Barrels of Oil" after Sinopec and PetroChina .
Time of Update: 2022-02-22
S. FDA approved the international Phase IIb clinical trial of Soyuan Bio’s first-in-class drug DB104 (liafensine) against refractory depression (TRD).
Suoyuan Bio will initiate this international Phase IIb clinical trial based on FDA approval to evaluate the safety and efficacy of DB104 in TRD patients .
Guiyang intends to establish industry guidance fund for comprehensive utilization of phosphogypsum resources
Time of Update: 2022-02-20
? According to the "Ten Measures", Guiyang City will set up a high-tech industry guidance fund for the comprehensive utilization of phosphogypsum resources with a total scale of 500 million yuan.
The State Food and Drug Administration has conditionally approved the marketing of icariin soft capsules for the treatment of hepatocellular carcinoma
Time of Update: 2022-01-25
The State Food and Drug Administration requires the holder of the marketing authorization of this variety to continue to complete the relevant post-marketing research work in accordance with the attached conditions and requirements .
Researchers report brain-based approach to determining marijuana intoxication damage
Time of Update: 2022-01-24
Researchers at Massachusetts General Hospital (MGH) have found that a non-invasive brain imaging procedure is an objectively reliable way to identify those whose performance is impaired by THC, the psychoactive component in marijuana.
Xinlitai Class 1 New Drug Application for Clinical Treatment of Major Depression
Time of Update: 2022-01-11
1%; the lifetime prevalence of depression in Chinese adults is 6.
With the improvement of living standards and the increase of people's health awareness, it is expected that the market for depression will continue to expand .
HER2 dual anti-KN026 combined with chemotherapy for the treatment of gastric cancer is clinically approved
Time of Update: 2022-01-07
KN026-CSP-001 is a randomized, multicenter, phase II/III clinical study to evaluate the effectiveness and safety of KN026 combined with chemotherapy in patients with HER2-positive gastric cancer (including gastric-esophageal junction adenocarcinoma) who have failed first-line treatment , Professor Xu Jianming from the General Hospital of the Chinese People’s Liberation Army served as the principal investigator .
New drug development Arnold Pharma's oral PD-L1 inhibitor AN4005 is approved by NMPA to start clinical trials
Time of Update: 2021-12-29
He Nanhai, head of Arnold Pharma's global research and development, said: As a small molecule PD-L1 inhibitor, AN4005 has shown good anti-tumor activity, and it will have a huge future in monotherapy and combination with other products of the company.